We aimed to investigate the relationship between platelet-to-lymphocyte ratio (PLR) and contrast-induced acute kidney injury (CI-AKI) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). A total of 2563 patients diagnosed with STEMI and underwent primary pPCI were retrospectively included in the study. Levels of PLR and creatinine were measured before and at 72 hours after pPCI. Patients were divided into 2 groups: non-CI-AKI group and CI-AKI group. Contrast-induced acute kidney injury occurred in 6.4% of the overall study population. Patients in the CI-AKI group had significantly higher PLR than those in the non-CI-AKI group (169.18 ± 81.01 vs 149.49 ± 74.54, P < .001). In logistic regression analysis, PLR was an independent predictor of CI-AKI (odds ratio [OR]: 1.774, 95% CI: 1.243-2.532, P = .002), along with age, use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker prior to the procedure, preprocedural creatinine level, amount of contrast material used during the procedure, and hypertension. Increased PLR levels are independently associated with a greater risk of CI-AKI in patients undergoing primary PCI for STEMI.
McCulloughPA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419–1428.
2.
Recio-MayoralAChaparroMPradoB. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol. 2007;49(12):1283–1288.
LazarosGTsiachrisDTousoulisD. In-hospital worsening renal function is an independent predictor of one-year mortality in patients with acute myocardial infarction. Int J Cardiol. 2012;155(1):97–101.
5.
BartholomewBAHarjaiKJDukkipatiS. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93(12):1515–1519.
6.
RussoDMinutoloRCianciarusoBMemoliBConteGDe NicolaL. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol. 1995;6(5):1451–1458.
7.
GoldenbergIMatetzkyS. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461–1471.
8.
HeymanSNRosenSKhamaisiMIdeeJMRosenbergerC. Hypoxia, oxidative stress and the pathophysiology of contrast media-induced nephropathy. In: MiyataTEckardtKWNangakuM, eds. Oxidative Stress in Basic Research and Clinical Practice: Studies on Renal Disorders. New York: Humana Press/Springer Science; 2011:229–256.
9.
HeymanSNRosenSRosenbergerC. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol. 2008;3(1):288–296.
10.
HeymanSNRosenSKhamaisiMIdéeJMRosenbergerC. Reactive oxygen species and the pathogenesis of radio contrast induced nephropathy. Invest Radiol. 2010;45(4):188–195.
11.
ThomsenHSMorcosSKBarrettBJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol. 2008;49(6):646–657.
12.
UgurMGulMBozbayM. The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention. Blood Coagul Fibrinolysis. 2014;25(8):806–811.
13.
AzabBShahNAkermanMMcGinnJTJr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST elevation myocardial infarction. J Thromb Thrombolysis. 2012;34(3):326–334.
14.
KurtulAYarliogluesMMuratSN. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol. 2014;114(3):342–347.
15.
ThygesenKAlpertJSWhiteHD. ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–2567.
16.
JaffeASAppleFSGalvaniM. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634–2653.
17.
ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250–1259.
18.
AndrassyKM. Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;84(3):622–623.
19.
MehranRNikolskyE. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;(100):S11–S15.
20.
Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5–37.
21.
ManciaGDe BackerGDominiczakA. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187.
22.
ManciaGFagardRNarkiewiczK. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219.
23.
NashKHafeezAHouS. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–936.
24.
ChenSLZhangJYeiF. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol. 2008;126(3):407–413.
25.
MehranRAymongEDNikolskyE. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–1399.
26.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Contrast-induced nephropathy: an “all or none” phenomenon?Angiology. 2015;66(6):508–513.
27.
AbaciOHarmankayaOKocasB. Long-term follow-up of patients at high risk for nephropathy after contrast exposure. Angiology. 2015;66(6):514–518.
28.
BrownJRDeVriesJTPiperWD; Northern New England Cardiovascular Disease Study Group. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J. 2008;155(5):260–266.
29.
AkcayANguyenQEdelsteinCL. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009;2009:137072.
30.
KadriZDanchinNVaurL; USIC 2000 Investigators. Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study. Heart. 2006;92(7):910–915.
31.
KayaAKayaYTopçuS. Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology. 2014;65(1):51–56.
32.
SmithRAGhanehPSuttonRRaratyMCampbellFNeoptolemosJP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008;12(8):1422–1428.
33.
WangDYangJXCaoDY. Preoperative neutrophil–lymphocyte and platelet–lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther. 2013;6:211–216.
34.
BalciKGBalciMMSenF. The role of baseline indirect inflammatory markers in prediction of response to cardiac resynchronisation therapy. Kardiol Pol. 2016;74(2):119–126.
35.
AkbogaMKCanpolatUYukselM. Platelet to lymphocyte ratio as a novel indicator of inflammation is correlated with the severity of metabolic syndrome: a single center large-scale study. Platelets. 2016;27(2):178–183.
36.
AkbogaMKCanpolatUYayla. Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in patients with stable coronary artery disease. Angiology. 2016;67(1):89–95.
37.
YaylaÇCanpolatUAkyelA. Association between platelet to lymphocyte ratio and saphenous vein graft disease. Angiology. 2016;67(2):133–138.
38.
YaylaÇAkboğaMKCanpolatU. Platelet to lymphocyte ratio can be a predictor of infarct-related artery patency in patients with ST-segment elevation myocardial infarction. Angiology. 2015;66(9):831–836.
39.
GaryTPichlerMBelajK. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS One. 2013;8(7):676–688.
40.
ZouridakisEGGarcia-MollXKaskiJC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol. 2000;86(4):449–451.
41.
OmmenSRHodgeDORodehefferRJMcGregorCGThomsonSPGibbonsRJ. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation. 1998;97(1):19–22.
42.
NikolskyEGrinesCLCoxDA. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). Am J Cardiol. 2007;99(8):1055–1061.
43.
BaltaSDemırkolSKucukU. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice. Hemodial Int. 2013;17(4):668–669.
44.
BriguoriCAiroldiFD’AndreaD. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115(10):1211–1217.
45.
AkanHGüvenNAydogduIAratMBeksaçMDalvaK. Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. Acta Haematol. 2000;103(3):152–156.
46.
KadikoyluGYavasogluIBolamanZSenturkT. Platelet parameters in women with iron deficiency anemia. J Natl Med Assoc. 2006;98(3):398–402.
47.
KukuIKayaEYologluSGokdenizRBaydinA. Platelet counts in adults with iron deficiency anemia. Platelets. 2009;20(6):401–405.
48.
KeungYKOwenJ. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemost. 2004;10(4):387–391.
49.
StolzEValduezaJMGrebeM. Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. J Neurol. 2007;254(6):729–734.
50.
SonnebornD. Thrombocytopenia and iron deficiency. Ann Intern Med. 1974;80(1):111.
51.
PerlmanMKSchwabJGNachmanJBRubinCM. Thrombocytopenia in children with severe iron deficiency. J Pediatr Hematol Oncol. 2002;24(5):380–384.
52.
KocasCYildizAAbaciO. Platelet-to-lymphocyte ratio predicts contrast-induced nephropathy in patients with non-ST-segment elevation acute coronary syndrome. Angiology. 2015;66(10):964–968.
53.
HammCWBassandJPAgewallS; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.
54.
WindeckerSKolhPAlfonsoF. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–2619.
55.
AkyuzSYaylakBAltaySKasikciogluHCamN. The role of statins in preventing contrast-induced acute kidney injury: a narrative review. Angiology. 2015;66(8):701–707.
